Biosensor

CardiAI and Carleton University Forge Innovative Partnership to Revolutionize Medical Diagnostics

Retrieved on: 
Tuesday, February 27, 2024
AB, Electrolyte, EMR, Hospital, Research, Partnership, Biosensor, Electronic health record, Biomarker, Saliva, Associate, Carleton University, Marriage

CardiAI and Carleton are joining forces to harness the potential of EG-FET biosensors for the detection of critical biomarkers in saliva and whole blood.

Key Points: 
  • CardiAI and Carleton are joining forces to harness the potential of EG-FET biosensors for the detection of critical biomarkers in saliva and whole blood.
  • This collaborative effort will not only revolutionize point-of-care diagnostics, but also pave the way for expanding the technology's applications to a broader range of health conditions.
  • "We are thrilled to embark on this transformative journey with Carleton University," says Dr. Anmol S. Kapoor, Cardiologist and CEO of CardiAI.
  • Integration with BioAro's BioEMR: To maximize the potential of EG-FET biosensor technology, CardiAI and Carleton University will integrate it with BioAro's BioEMR – an AI-powered Telemedicine Platform and Electronic Medical Records (EMR) system.

EnLiSense CCM Advances Validation of Real-Time IBD Inflammatory Biomarker Monitoring with Two Recent Peer-Reviewed Longitudinal Studies

Retrieved on: 
Thursday, February 15, 2024
Hardware, Health Technology, Data Management, Other Health, Technology, Professional Services, Biometrics, Medical Devices, Genetics, Artificial Intelligence, Wearables, Mobile Technology, Biotechnology, Science, Data Analytics, Research, Health, Biosensor, Digital health, Ulcerative colitis, Senior, Doctor of Philosophy, Translation, Hasso Plattner Institute, Moses Austin, MD, Professor, Inflammation, Blood, IL-6, Quality of life, Bioelectronics, Gastrointestinal tract, Trial of the century, Scientific Reports, Management, University, Perspiration, CRP, Clinical, Inflammatory bowel disease, Patient, Biological engineering, Optimism, IBD, Conditional sentence, TNF, Endoscopy, National Institutes of Health, Medical imaging

Our innovative IBD Aware device offers the first solution for continuous, non-invasive monitoring of IBD through the power of sweat-sensing technology.

Key Points: 
  • Our innovative IBD Aware device offers the first solution for continuous, non-invasive monitoring of IBD through the power of sweat-sensing technology.
  • EnLiSense's journey reaches a significant milestone with over half a million human biomarker readings, underscoring the extensive validation of our technology.
  • These readings provide crucial data points, enhancing the precision and trustworthiness of inflammatory biomarker monitoring.
  • The studies involved measuring inflammation markers CRP, TNF-α, and IL-6 in subjects' blood and sweat continuously in subjects with and without IBD.

Study of First Affordable and Rapid Test for Beta Thalassemia Performs at 99% Accuracy in Diagnosing the Blood Disorder

Retrieved on: 
Monday, February 5, 2024
Medicine, Survival, Beta thalassemia, Trial of the century, MD, Child, Diagnosis, Incidence, Marriage, Gazelle, Biosensor, Patient, Disease, European Journal, Hematology, HPLC, Pharmaceutical industry

This study concluded that Gazelle provides, for the first time, an affordable and rapid solution for identifying beta-thal at point of care.

Key Points: 
  • This study concluded that Gazelle provides, for the first time, an affordable and rapid solution for identifying beta-thal at point of care.
  • The ability to test accurately and rapidly (results are available in 8 minutes) as demonstrated in this study suggests that Gazelle is suitable for large-scale testing of beta-thal at point of care.
  • Beta thalassemia is an inherited blood disorder.
  • A study published in the European Journal of Hematology has shown, however, that incidence rates decrease in areas with screening and education programs.

Biosensors and Nanosensors Propel Towards a $43.5 Billion Global Market by 2028 - BCC Research Analysis Unveiled

Retrieved on: 
Wednesday, January 31, 2024
Wearable, Nanotechnology, Microfluidics, Growth, Internet of things, Research, Nanoparticle, Miniaturization, International finance, Nanosensor, Nano, Environmental monitoring, Integration, Sensor, Biosensor, Nanocomposite, Heart rate, Algorithm, BCC, Artificial intelligence, Geography, Health, Market, Medical imaging

BOSTON, Jan. 31, 2024 /PRNewswire/ -- Biosensors and nanosensors represent cutting-edge technologies that have significantly advanced the landscape of global markets. Biosensors are analytical devices that combine biological components with sensors to detect and quantify specific substances, offering applications in healthcare, environmental monitoring, and more. Nanosensors, operating at the nanoscale, leverage nanotechnology to enhance precision and sensitivity in detecting various analytes. The global market for these technologies is characterized by rapid advancements, fueled by innovations in nanotechnology, IoT integration, and miniaturization. These sensors find extensive application in healthcare diagnostics, environmental monitoring, and various industries. This report delves into the dynamic market trends and technologies shaping the biosensors and nanosensors arena, providing valuable insights into the transformative potential of these innovations on a global scale.

Key Points: 
  • The global market for these technologies is characterized by rapid advancements, fueled by innovations in nanotechnology, IoT integration, and miniaturization.
  • "According to the latest BCC Research study, the demand for Biosensors and Nanosensors: Global Markets and Technologies is estimated to increase from $30.6.0 billion in 2023 to reach $43.5 billion by 2028, at a compound annual growth rate (CAGR) of 7.3% from 2023 through 2028."
  • This comprehensive report delves into the intricate details of the worldwide biosensors and nanosensors market, providing a meticulous analysis categorized by product type, technology, application, and geography.
  • The narrative elucidates the primary drivers propelling the global biosensors and nanosensors market, coupled with regional dynamics and prevailing industry trends.

BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP

Retrieved on: 
Tuesday, November 7, 2023
Biosensor, Sale, PURE, Nautilus, Inc. v. Biosig Instruments, Inc., Johnson & Johnson, Atrial fibrillation, J & J, J&J, Executive, Electrophysiology, CRM, General surgery, Boston Scientific, Johnson, Management

Mr. Hrkac has a 32-year career in medical devices, as an executive and corporate director, covering much of the globe.

Key Points: 
  • Mr. Hrkac has a 32-year career in medical devices, as an executive and corporate director, covering much of the globe.
  • Since April 2022, he has served on the BioSig Board of Directors and as Chairman of the nominating and corporate governance committee.
  • “Fred is well-known as a key executive leader in the global medical device industry.
  • Mr. Hrkac currently serves on the board of Serres in Helsinki, Finland, and Spineart in Geneva, Switzerland as chairman of the board.

Medical Waste Management Market to Reach US$15.3B by 2033 as Demand Grows to Reduce Environmental Hazards and Protect Health | Future Market Insights, Inc.

Retrieved on: 
Wednesday, October 18, 2023
Biosensor, United Kingdom, Radioactive waste, Clean Harbors, Waste management, Associate, Sharps waste, Veolia, Comprehensive, Stericycle, Sample, Growth, Garbage, Transport, Hospital, Biodegradable waste, Benchmarking, Public, Safety, Landfill, Recycling

NEWARK, Del., Oct. 18, 2023 /PRNewswire/ -- In terms of value, the global net demand for medical waste management systems was estimated to be around US$ 7,592.9 million in 2022. The overall market for medical waste management systems is projected to grow at an annual rate of 6.6% between 2023 and 2033. Following this promising growth rate, the global market value is poised to reach a valuation of around US$ 15,336.9 million by 2033.

Key Points: 
  • The global medical waste management market is expected to reach US$15.3 billion by 2033, driven by the need to reduce environmental hazards and avoid adverse health outcomes.
  • Medical waste streams require specialized knowledge, tools, and disposal techniques, which makes specialized medical waste management services essential
    Analysis of the Medical Waste Management System Market by Bio Hazardous Waste, Non-hazardous Waste, Sharps Waste, Pharmaceutical Waste, Radioactive Waste, and Other Wastes, Opportunities and Forecast 2023-2033
    NEWARK, Del., Oct. 18, 2023 /PRNewswire/ -- In terms of value, the global net demand for medical waste management systems was estimated to be around US$ 7,592.9 million in 2022.
  • The overall market for medical waste management systems is projected to grow at an annual rate of 6.6% between 2023 and 2033.
  • Particularly, there is a rising need for specialist medical waste management services that handle and eliminate different radioactive or infectious waste.

Medical Waste Management Market to Reach US$15.3B by 2033 as Demand Grows to Reduce Environmental Hazards and Protect Health | Future Market Insights, Inc.

Retrieved on: 
Wednesday, October 18, 2023
Biosensor, United Kingdom, Radioactive waste, Clean Harbors, Waste management, Associate, Sharps waste, Veolia, Comprehensive, Stericycle, Sample, Growth, Garbage, Transport, Hospital, Biodegradable waste, Benchmarking, Public, Safety, Landfill, Recycling

NEWARK, Del., Oct. 18, 2023 /PRNewswire/ -- In terms of value, the global net demand for medical waste management systems was estimated to be around US$ 7,592.9 million in 2022. The overall market for medical waste management systems is projected to grow at an annual rate of 6.6% between 2023 and 2033. Following this promising growth rate, the global market value is poised to reach a valuation of around US$ 15,336.9 million by 2033.

Key Points: 
  • The global medical waste management market is expected to reach US$15.3 billion by 2033, driven by the need to reduce environmental hazards and avoid adverse health outcomes.
  • Medical waste streams require specialized knowledge, tools, and disposal techniques, which makes specialized medical waste management services essential
    Analysis of the Medical Waste Management System Market by Bio Hazardous Waste, Non-hazardous Waste, Sharps Waste, Pharmaceutical Waste, Radioactive Waste, and Other Wastes, Opportunities and Forecast 2023-2033
    NEWARK, Del., Oct. 18, 2023 /PRNewswire/ -- In terms of value, the global net demand for medical waste management systems was estimated to be around US$ 7,592.9 million in 2022.
  • The overall market for medical waste management systems is projected to grow at an annual rate of 6.6% between 2023 and 2033.
  • Particularly, there is a rising need for specialist medical waste management services that handle and eliminate different radioactive or infectious waste.

SD Biosensor Inc. Held an ESG Management Proclamation Ceremony Focusing on 'Sustainable Growth for People and the Earth'

Retrieved on: 
Friday, September 15, 2023
Environmental management system, Communication, ISO, Corporate governance, Biosensor, Orientation, Jeungpyeong County, Happiness, Biophysical environment, ESG, Social, Health, SD, Management

In the proclamation ceremony, the executives and employees from the Korean headquarters, European and Asian subsidiaries took part online, shared strategic tasks that can be practiced and shared the idea of conversion to ESG management system.

Key Points: 
  • In the proclamation ceremony, the executives and employees from the Korean headquarters, European and Asian subsidiaries took part online, shared strategic tasks that can be practiced and shared the idea of conversion to ESG management system.
  • SD Biosensor presented its ESG management vision as 'the company contributing to improvement of sustainability for people and the earth through innovative technologies' and disclosed its orientation to ESG management.
  • SD Biosensor, through systemic management from its early phase of establishment, acquired Environmental Management System ISO 14001*.
  • By promoting enterprise-wide ESG management and internalizing communication culture to strengthen corporate sustainability and soundness, it is building a transparent and sound governance structure.

Europe Point-of-Care, Biosensors and Rapid Diagnostics Conference 2023: From Novel Technologies to Regulatory Approval (Rotterdam, Netherlands - June 19-20, 2023) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023
Health, Other Health, Engineering, Biosensor, Pandemic, Chemistry, Biosurveillance, Biology, POC, Imperial College London, Medical device, Vaccine

The "Point-of-Care, Biosensors and Rapid Diagnostics Europe 2023" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Point-of-Care, Biosensors and Rapid Diagnostics Europe 2023" training has been added to ResearchAndMarkets.com's offering.
  • This conference will provide an overview of the point-of-care (POC) testing landscape, from novel technologies to regulatory approval.
  • Emphasis will be placed on mobile diagnostics platforms and convergence with microfluidics-based and lab-on-a-chip approaches.
  • Next Generation Technologies for Pathogen Detection: Pandemics and Biosurveillance
    Rapid Biodetection of Pathogens and Threat Identification: Pandemics and Biosurveillance
    Professor of Biomedical Sensors Engineering, Imperial College London
    Head of Division Microfluidic Platforms, Hahn-Schickard-Gesellschaft fur Angewandte Forschung eV

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Third Quarter Financial Results and Operational Highlights

Retrieved on: 
Thursday, May 11, 2023
Federal Food, Drug, and Cosmetic Act, De novo, University, Accreditation, Initiate, Marketing, Law enforcement, Food, NATA, Research, Biosensor, Government, U.S. FDA, Organization, TTR, Acquisition, Patent, United Kingdom, FDA, Intelligence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Saliva, Pharmaceutical industry, Cryptocurrency, Television, Medical device, Drug, Video game, Hozelock

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions,” “INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal third quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • - Filed 513(g) submission with U.S. FDA for Intelligent Fingerprinting Drug Screening Cartridge -
    - Completion of Milestone 7, key phase of biosensor platform development -
    NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions,” “INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal third quarter ended March 31, 2023, and provided a business update.
  • “INBS delivered revenue growth during the third quarter and achieved several important milestones in line with our regional expansion plans,” said Harry Simeonidis, Chief Executive Officer at Intelligent Bio Solutions.
  • The results showed a record 4x improvement in time-to-result (TTR), enabling the biosensor to return test results in under one minute.
  • Third Quarter Ended March 31, 2023, Financial Results
    All amounts are expressed in U.S. dollars unless indicated otherwise.